A Randomized, Double-blind, Placebo-controlled Single and Multiple Dose Phase I Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetics of Topical Ointment YR001 in Adult Healthy Volunteers
Latest Information Update: 31 Jan 2024
At a glance
- Drugs YR 001 (Primary)
- Indications Atopic dermatitis; Psoriasis
- Focus Adverse reactions
- Sponsors YIRUI Pharmaceutical Technology
Most Recent Events
- 22 Jan 2024 Status changed from recruiting to completed.
- 24 May 2023 Status changed from not yet recruiting to recruiting.
- 15 Feb 2023 New trial record